This announcement is a separate document:
信達生物：自願公告 - 達伯舒（信迪利單抗注射液）新增第七項適應症、達攸同（貝伐珠單抗注射液）新增第八項適應症納入2023年版國家醫保藥品目錄
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE CHINA NATIONAL REIMBURSEMENT DRUG LIST (2023 VERSION) OF TYVYT''S SEVENTH INDICATION AND BYVASDA''S EIGHTH INDICATION
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.